|
30 Dec 2020 |
Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
|
|
29 Dec 2020 |
Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS
|
|
28 Dec 2020 |
Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
|
|
23 Dec 2020 |
Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
|
|
23 Dec 2020 |
Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome
|
|
23 Dec 2020 |
OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
|
|
23 Dec 2020 |
Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Canc
|
|
23 Dec 2020 |
Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review
|
|
22 Dec 2020 |
Ridgeback Biotherapeutics LP Announces the Approval of EbangaTM for Ebola
|
|
22 Dec 2020 |
Update on SOURCE Phase III trial for tezepelumab in patients with severe, oral corticosteroid-dependent asthma
|
|
22 Dec 2020 |
Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of Blindness
|
|
18 Dec 2020 |
New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
|
|
18 Dec 2020 |
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
|
|
18 Dec 2020 |
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
|
|
18 Dec 2020 |
Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
|
|
18 Dec 2020 |
Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies
|
|
18 Dec 2020 |
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
|
|
18 Dec 2020 |
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
|
|
18 Dec 2020 |
FDA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
|
|
18 Dec 2020 |
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophageal Junction Cancer
|
|
18 Dec 2020 |
FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
|
|
18 Dec 2020 |
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
|
|
17 Dec 2020 |
Regeneron Provides Update on Odronextamab Clinical Trials in B-cell Non-Hodgkin Lymphomas
|
|
17 Dec 2020 |
Imfinzi recommended for approval in the EU by CHMP for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
|
|
16 Dec 2020 |
Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma
|
